MX2022011596A - Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae. - Google Patents
Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae.Info
- Publication number
- MX2022011596A MX2022011596A MX2022011596A MX2022011596A MX2022011596A MX 2022011596 A MX2022011596 A MX 2022011596A MX 2022011596 A MX2022011596 A MX 2022011596A MX 2022011596 A MX2022011596 A MX 2022011596A MX 2022011596 A MX2022011596 A MX 2022011596A
- Authority
- MX
- Mexico
- Prior art keywords
- coronaviridae infection
- compounds
- methods
- coronaviridae
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305299.8A EP3881844A1 (en) | 2020-03-20 | 2020-03-20 | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP20305327.7A EP3884946A1 (en) | 2020-03-25 | 2020-03-25 | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP20305482 | 2020-05-12 | ||
| EP20306483 | 2020-12-03 | ||
| PCT/EP2021/057123 WO2021186053A1 (en) | 2020-03-20 | 2021-03-19 | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011596A true MX2022011596A (es) | 2022-10-18 |
Family
ID=74884979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011596A MX2022011596A (es) | 2020-03-20 | 2021-03-19 | Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230142547A1 (https=) |
| EP (1) | EP4121053A1 (https=) |
| JP (1) | JP2023521564A (https=) |
| KR (1) | KR20220152292A (https=) |
| CN (1) | CN115605205A (https=) |
| AU (1) | AU2021238792A1 (https=) |
| BR (1) | BR112022018793A2 (https=) |
| CA (1) | CA3172179A1 (https=) |
| IL (1) | IL296522A (https=) |
| MX (1) | MX2022011596A (https=) |
| WO (1) | WO2021186053A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
| CN118373771A (zh) * | 2023-01-20 | 2024-07-23 | 江苏柯菲平医药股份有限公司 | 一种喹啉衍生化合物或其可药用的盐及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070225363A1 (en) | 2003-11-21 | 2007-09-27 | The University Of Newcastle Research Associates Ltd. | Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis |
| SI2440547T1 (sl) | 2009-06-12 | 2023-05-31 | Abivax | Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| EP2862928A1 (en) | 2013-10-18 | 2015-04-22 | Université de Strasbourg | Dynamin 2 inhibitor for the treatment of centronuclear myopathies |
| EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| EP3059236A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| EP3594206A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3858815A1 (en) * | 2020-01-31 | 2021-08-04 | Abivax | Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| CA3164700A1 (en) * | 2020-01-31 | 2021-08-05 | Abivax | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| KR20210151949A (ko) * | 2020-04-05 | 2021-12-14 | 화이자 인코포레이티드 | Covid-19의 치료를 위한 화합물 및 방법 |
-
2021
- 2021-03-19 US US17/913,063 patent/US20230142547A1/en active Pending
- 2021-03-19 JP JP2022556017A patent/JP2023521564A/ja active Pending
- 2021-03-19 BR BR112022018793A patent/BR112022018793A2/pt unknown
- 2021-03-19 MX MX2022011596A patent/MX2022011596A/es unknown
- 2021-03-19 CN CN202180034076.4A patent/CN115605205A/zh active Pending
- 2021-03-19 CA CA3172179A patent/CA3172179A1/en active Pending
- 2021-03-19 AU AU2021238792A patent/AU2021238792A1/en not_active Abandoned
- 2021-03-19 IL IL296522A patent/IL296522A/en unknown
- 2021-03-19 KR KR1020227035066A patent/KR20220152292A/ko not_active Ceased
- 2021-03-19 EP EP21712534.3A patent/EP4121053A1/en active Pending
- 2021-03-19 WO PCT/EP2021/057123 patent/WO2021186053A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023521564A (ja) | 2023-05-25 |
| EP4121053A1 (en) | 2023-01-25 |
| AU2021238792A1 (en) | 2022-10-13 |
| BR112022018793A2 (pt) | 2022-11-29 |
| WO2021186053A1 (en) | 2021-09-23 |
| CA3172179A1 (en) | 2021-09-23 |
| KR20220152292A (ko) | 2022-11-15 |
| CN115605205A (zh) | 2023-01-13 |
| US20230142547A1 (en) | 2023-05-11 |
| IL296522A (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023009521A (es) | Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d. | |
| AR052399A1 (es) | Metodo para tratar o prevenir una infeccion causada por microbios, composicion para el mismo y metodos para desinfectar dispositivos y para prevenir las infecciones que se originan en dispositivos medicos | |
| BR112023024501A2 (pt) | Método de tratamento da síndrome de down, método de melhora de eficácia de uma vacina e método de tratamento de câncer | |
| ATE555810T1 (de) | Mittel zur behandlung oder prävention von verdauungsgeschwüren | |
| CL2022000214A1 (es) | Inhibidores de enzimas | |
| BR112022014861A2 (pt) | Métodos de tratamento para deficiência de alfa-1 antittripsina | |
| CR20210103A (es) | Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5 | |
| MX2022011596A (es) | Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae. | |
| CL2023002746A1 (es) | Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas | |
| PH12021551070A1 (en) | Pharmaceutical composition comprising histone deacetylase 6 inhibitors | |
| BR112022013646A2 (pt) | Método de tratamento de esplenomegalia | |
| BR112021025732A2 (pt) | Inibidores macrocíclicos de mcl-1 | |
| BR112022024999A2 (pt) | Inibidor tlr7 em combinação com prednisolona ou hidroxicloroquina para o tratamento do lúpus eritematoso cutâneo | |
| BR112018076800A2 (pt) | derivado de guanidina, medicamento, inibidor da proteína 1 da translocação de linfoma de tecido linfóide associado com mucosa, e, agente terapêutico ou profilático. | |
| MX2021015513A (es) | Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelicula. | |
| BR112022018396A2 (pt) | Método de tratamento ou prevenção para insuficiência cardíaca crônica | |
| AR127533A1 (es) | INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS | |
| CO2025016290A2 (es) | Compuestos anti-vih | |
| MX2021009219A (es) | Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria. | |
| BR112023002292A2 (pt) | Composições farmacêuticas para o tratamento e prevenção de infecções do trato urinário | |
| MX2023011442A (es) | Un inhibidor de pi3k-delta para usarse en regimenes de tratamiento. | |
| BR112022018477A2 (pt) | Composto derivado de pirimidina, composição compreendendo o mesmo, e seus usos na prevenção ou tratamento de doenças neurodegenerativas e câncer | |
| MX2022005388A (es) | Compuestos de pirrolidina y piperidina. | |
| BR112023020732A2 (pt) | Vetor lentiviral para o tratamento da hepatite b, método e preparação de partículas lentivirais para o tratamento da mesma e composição farmacêutica para o tratamento e/ou prevenção da infecção pelo vírus da hepatite b | |
| ZA202210027B (en) | Compositions of vitamin a palmitate, processes for their preparation, uses and methods comprising them |